0000899243-21-041967.txt : 20211028 0000899243-21-041967.hdr.sgml : 20211028 20211028203012 ACCESSION NUMBER: 0000899243-21-041967 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211028 FILED AS OF DATE: 20211028 DATE AS OF CHANGE: 20211028 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: de los Pinos Elisabet CENTRAL INDEX KEY: 0001889633 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40971 FILM NUMBER: 211360134 MAIL ADDRESS: STREET 1: C/O AURA BIOSCIENCES, INC. STREET 2: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aura Biosciences, Inc. CENTRAL INDEX KEY: 0001501796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 320271970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617)500-8864 MAIL ADDRESS: STREET 1: 85 BOLTON STREET CITY: CAMBRIDGE STATE: MA ZIP: 02140 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-10-28 0 0001501796 Aura Biosciences, Inc. AURA 0001889633 de los Pinos Elisabet C/O AURA BIOSCIENCES, INC. 85 BOLTON STREET CAMBRIDGE MA 02140 1 1 0 0 Chief Executive Officer Common Stock 126860 I By: EdIP Revocable Trust Stock Option (Right to Buy) 5.48 2021-10-28 Common Stock 3649 D Stock Option (Right to Buy) 5.75 2024-10-01 Common Stock 5474 D Stock Option (Right to Buy) 5.07 2025-06-02 Common Stock 10948 D Stock Option (Right to Buy) 5.48 2026-04-11 Common Stock 14598 D Stock Option (Right to Buy) 5.21 2027-07-07 Common Stock 14598 D Stock Option (Right to Buy) 2.74 2028-02-21 Common Stock 364963 D Stock Option (Right to Buy) 3.15 2029-02-06 Common Stock 63548 D Stock Option (Right to Buy) 4.25 2030-03-16 Common Stock 194889 D Stock Option (Right to Buy) 5.48 2031-06-28 Common Stock 620437 D Series A-1 Preferred Stock Common Stock 3042 I By: EdIP Revocable Trust Series A-2 Preferred Stock Common Stock 1510 I By: EdIP Revocable Trust The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee. This option is fully vested. The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 21, 2018. The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2019 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2020. The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021. Immediately prior to the completion of the Issuer's initial public offering, each share of Series A-1 Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock, on a 13.7-for-one basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series A-1 Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. Immediately prior to the completion of the Issuer's initial public offering, each share of Series A-2 Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock, on a 13.7-for-one basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series A-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. /s/ Julie Feder 2021-10-28 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                  POWER OF ATTORNEY


      The undersigned hereby constitutes and appoints each of Julie Feder and
Christopher Primiano, and with full power of substitution, the undersigned's
true and lawful attorney-in-fact to:

      (1)     execute for and on behalf of the undersigned, in the undersigned's
capacity as officer and/or director of Aura Biosciences, Inc., a Delaware
corporation (the "Company"), from time to time the following U.S. Securities and
Exchange Commission (the "SEC") forms: (i) Form ID, including any attached
documents (such as Update Passphrase Authentication), to effect the assignment
of codes to the undersigned to be used in the transmission of information to the
SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial
Ownership of Securities, including any attached documents; (iii) Form 4,
Statement of Changes in Beneficial Ownership of Securities, including any
attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of
Securities in accordance with Section 16(a) of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and the rules thereunder, including any
attached documents; and (v) amendments of each thereof, in accordance with the
Exchange Act, and the rules thereunder, including any attached documents;

      (2)     do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any such
Form 3, 4 or 5 or any amendment(s) thereto and timely file such form(s) with the
SEC and any securities exchange, national association or similar authority; and

      (3)     take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

      The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company
from and against any demand, damage, loss, cost or expense arising from any
false or misleading information provided by the undersigned to the attorneys-in-
fact.

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company.

                            [Signature Page Follows]


      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of 19th day of October, 2021.


                                        /s/ Elisabet de los Pinos
                                        ----------------------------------
                                        Signature

                                        Name:  Elisabet de los Pinos